<PAGE>
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only (as permitted
by Rule 14a-6(e)(2))
[X] Definitive Proxy Statement
[ ] Definitive Additional Materials
[ ] Soliciting Material Pursuant to Sec. 240.14a-11(c) or Sec. 240.14a-12
XOMED SURGICAL PRODUCTS, INC.
(Name of Registrant as Specified in its Charter)
Not Applicable
------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14(a)-6(i)(1) and 0-11.
1) Title of each class of securities to which transaction applies:
----------------------------------------------------------------------
2) Aggregate number of securities to which transaction applies:
----------------------------------------------------------------------
3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
----------------------------------------------------------------------
4) Proposed maximum aggregate value of transaction:
----------------------------------------------------------------------
5) Total Fee Paid:
----------------------------------------------------------------------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee
was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.
1) Amount Previously Paid:
-----------------------------------------------------------------------
2) Form, Schedule or Registration Statement No.:
-----------------------------------------------------------------------
3) Filing Party:
-----------------------------------------------------------------------
4) Date Filed
-----------------------------------------------------------------------
<PAGE>
XOMED SURGICAL PRODUCTS, INC.
--------------------
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS
--------------------
MAY 28, 1997
--------------------
To the Stockholders of
XOMED SURGICAL PRODUCTS, INC.
The annual meeting of stockholders (the "Annual Meeting") of Xomed
Surgical Products, Inc., a Delaware corporation (the "Company"), will be held at
the offices of the Company, 6743 Southpoint Drive North, Jacksonville, Florida
32216 on Wednesday, May 28, 1997, at 3:30 P.M., Jacksonville time, for the
following purposes:
1. To elect seven Directors to the Company's Board of
Directors;
2. To approve amendments to the Company's Stock Option Plan
to, among other things, increase the number of shares of
the Company's Common Stock, par value $.01 per share,
reserved for issuance thereunder by 300,000 shares;
3. To ratify the appointment by the Board of Directors of
Ernst & Young LLP as independent auditors for the Company
for the fiscal year ending December 31, 1997; and
4. To act upon such other business as may properly come
before the Annual Meeting or any adjournment or
postponement thereof.
The Board of Directors has fixed the close of business on April 15,
1997, as the record date for the determination of stockholders entitled to
receive notice of and to vote at the Annual Meeting and any adjournment or
postponement thereof.
By order of the Board of Directors,
/s/ Thomas E. Timbie
Thomas E. Timbie
Secretary
April 24, 1997
Your vote is important. Whether or not you expect to be present at the
Annual Meeting, please date and sign the enclosed proxy and return it promptly
in the enclosed envelope. You may revoke your proxy at any time before it is
voted at the Annual Meeting. In the event you attend the Annual Meeting and vote
in person, the proxy will not be used.
<PAGE>
XOMED SURGICAL PRODUCTS, INC.
6743 Southpoint Drive North
Jacksonville, Florida 32216
-----
PROXY STATEMENT
-----
This Proxy Statement (the "Proxy Statement") is furnished in connection
with the solicitation of proxies by the Board of Directors (the "Board of
Directors") of Xomed Surgical Products, Inc., a Delaware corporation (the
"Company"), to be voted at the annual meeting of stockholders of the Company to
be held on Wednesday, May 28, 1997, at 3:30 P.M., Jacksonville time, at the
offices of the Company, 6743 Southpoint Drive North, Jacksonville, Florida
32216, and at any adjournment or postponement thereof (the "Annual Meeting"). A
copy of the Company's Annual Report to Stockholders for the fiscal year ended
December 31, 1996, this Proxy Statement and the accompanying proxy card are
first being sent or given to stockholders on or about April 24, 1997.
Properly executed proxies received prior to the Annual Meeting, unless
revoked, will be voted in accordance with the specified instructions. Regarding
the election of Directors, stockholders may vote in favor of all nominees or
withhold their votes as to all nominees or withhold their votes as to specific
nominees. With respect to all other proposals to be voted upon, stockholders may
vote in favor of a proposal, against a proposal or may abstain from voting.
Stockholders should specify their choices on the enclosed proxy card. If no
instructions are given with respect to the matters to be acted upon, the persons
named in the proxy solicited by the Board of Directors intend to vote FOR the
election of the Directors listed below, FOR approval of the amendments to the
Company's 1996 Stock Option Plan (the "Stock Option Plan") and FOR ratification
of the appointment by the Board of Directors of Ernst & Young LLP as independent
auditors for the Company for the fiscal year ending December 31, 1997. If any
other matter should be presented at the Annual Meeting upon which a vote may
properly be taken, the shares represented by the proxy will be voted with
respect thereto by the person or persons holding such proxy as in their judgment
is in the best interests of the Company and its stockholders. The Board of
Directors does not know of any matters other than as described in the Notice of
Annual Meeting that are to come before the Annual Meeting.
Stockholders may vote by either completing and returning the enclosed
proxy card prior to the Annual Meeting, voting in person at the Annual Meeting
or submitting a signed proxy card at the Annual Meeting. Stockholders who
execute proxies may revoke them at any time before they are voted at the Annual
Meeting by written notice to the Secretary of the Company, by submitting a new
proxy or by personal ballot at the Annual Meeting.
The Board of Directors has fixed the close of business on April 15,
1997 as the Record Date (the "Record Date") for determining stockholders
entitled to notice of and to vote at the Annual Meeting.
As of the Record Date, the Company had 7,333,899 shares of Common
Stock, par value $.01 per share ("Common Stock"), outstanding and entitled to
vote at the Annual Meeting. The Common Stock is the only outstanding class of
voting securities of the Company. Each stockholder is entitled to one vote for
each share of Common Stock owned at the close of business on the Record Date.
The presence in person or by proxy of the holders of a majority of
outstanding shares of Common Stock is necessary to constitute a quorum in
connection with the transaction of business at the Annual Meeting. The
affirmative vote of a majority of shares of Common Stock present in person or by
proxy and entitled to vote at the Annual Meeting is required for election of
Directors, approval of the amendments to the Stock Option Plan and ratification
of the appointment of Ernst & Young LLP as independent auditors for the Company.
Broker "non-votes" (i.e., proxies from brokers or nominees indicating that such
persons have not received instructions from the beneficial owner or other
persons entitled to vote shares as to a matter with respect to which the
<PAGE>
brokers or nominees do not have discretionary power to vote) and shares for
which duly executed proxies have been received but with respect to which holders
of shares have abstained from voting will be treated as present for purposes of
determining the presence of a quorum at the Annual Meeting. Broker "non-votes"
are only counted for purposes of determining whether a quorum is present and,
therefore, will not be included in vote totals and will have no effect on the
outcome of the votes on the proposals to be acted upon at the Annual Meeting.
Abstentions will be counted as present and entitled to vote, and will have the
effect of a negative vote with respect to the proposals to be acted upon at the
Annual Meeting.
PROPOSAL ONE
ELECTION OF DIRECTORS
The Board of Directors, pursuant to the Company's Restated By-Laws, has
set the number of Directors of the Company at seven. Accordingly, seven
Directors are to be elected at the Annual Meeting to hold office until the next
annual meeting of stockholders and until their successors have been duly elected
and qualified. If a proxy is executed in such a manner as not to withhold
authority for the election of any or all of the nominees for Directors, then the
persons named in the proxy will vote the shares represented by the proxy for the
election of the seven nominees set forth below. If the proxy indicates that the
stockholder wishes to withhold a vote from one or more nominees for Directors,
such instructions will be followed by the persons named in the proxy. Each of
the nominees set forth below has consented to serve as a Director if elected at
the Annual Meeting. All of the nominees are currently members of the Board of
Directors.
Should any one or more of these nominees become unable to serve for any
reason, which is not anticipated, the Board of Directors may, unless the Board
of Directors by resolution provides for a lesser number of Directors, designate
substitute nominees, in which event the persons named in the enclosed proxy card
will vote for the election of such substitute nominee or nominees.
Nominees for Election as Directors
The respective ages, positions with the Company, business experience
during the past five years and directorships in other companies of the nominees
for election as Directors of the Company are set forth below.
James T. Treace, 51, has been President, Chief Executive Officer and
Chairman of the Board of Directors of the Company since April 1996. From 1993
until its acquisition by the Company in April 1996, Mr. Treace served as
President, Chairman of the Board of Directors and Chief Executive Officer of
TreBay Medical Corporation ("TreBay"), an ENT and orthopaedic product company
founded in 1993 by Mr. Treace and Mr. F. Barry Bays. From 1990 to 1993, Mr.
Treace served as President of Linvatec Corporation ("Linvatec"), a minimally
invasive orthopaedic medical device company formerly known as Concept, Inc.
("Concept"), which became a wholly owned subsidiary of Bristol-Myers Squibb
Company ("Bristol-Myers Squibb") in 1990. Mr. Treace served as President and
Chief Executive Officer of Concept from 1981 until its acquisition by
Bristol-Myers Squibb in 1990. Mr. Treace is the brother of John R. Treace and
Dan H. Treace, who are executive officers of the Company.
Richard B. Emmitt, 52, has served as a Director of the Company since
April 1994 and from December 1990 to 1994 was a Director of Merocel Corporation
("Merocel"), which became a subsidiary of the Company in 1994. Mr. Emmitt has
been a Managing Director of The Vertical Group, Inc., an investment firm, since
February 1989.
Paul H. Klingenstein, 41, has served as a Director of the Company since
April 1994. Mr. Klingenstein has been with Accel Partners, a venture capital
firm, since 1986, where he has been a General Partner since 1988. Mr.
Klingenstein is a Director of Aviron. He is also a Director of several privately
held health care and biopharmaceutical companies.
2
<PAGE>
William R. Miller, 68, has served as a Director of the Company since
April 1994 and from 1991 to 1994 was a Director of Merocel. In January 1991, Mr.
Miller retired as Vice Chairman of the Board of Directors of Bristol-Myers
Squibb. From 1985 to January 1991, Mr. Miller was a Director of Bristol-Myers
Squibb. Mr. Miller is a Director of Isis Pharmaceuticals, Inc., ImClone Systems,
Inc., St. Jude Medical, Inc., Transkaryotic Therapies, Inc. and Westvaco
Corporation. He is Chairman of the Board of Vion Pharmaceuticals, Inc. and SIBIA
Neurosciences, Inc. He is Vice Chairman of the Board of Trustees of the Cold
Spring Harbor Laboratory and is a past Chairman of the Board of the
Pharmaceutical Manufacturers Association. Mr. Miller is also: a Trustee of the
Manhattan School of Music, the Metropolitan Opera Association and the Opera
Orchestra of New York; Member of Oxford University Chancellor's Court of
Benefactors; Honorary Fellow of St. Edmund Hall; and Chairman of the
English-Speaking Union of the United States.
Rodman W. Moorhead, III, 53, has served as a Director of the Company
since 1994 and was a Director of Merocel from 1990 to 1994. Since 1973, he has
been with E.M. Warburg, Pincus & Co., LLC or its predecessor ("EMW LLC"), a
private investment firm, where he currently serves as a Senior Managing
Director. Mr. Moorhead is also a Director of NeXstar Pharmaceuticals, Inc.,
Value Health, Inc., Transkaryotic Therapies, Inc. and a number of privately held
companies.
James E. Thomas, 36, has served as a Director of the Company since
April 1994. Since 1989, he has been with EMW LLC, where he currently serves as a
Managing Director. Mr. Thomas is also a Director of Anergen, Inc., Celtrix
Pharmaceuticals, Inc., Menley & James Laboratories, Inc., Transkaryotic
Therapies, Inc. and several privately held companies.
Elizabeth H. Weatherman, 37, has served as a Director of the Company
since April 1994 and was a Director of Merocel from December 1990 until 1994.
Since 1988, she has been with EMW LLC, where she currently serves as a Managing
Director. Ms. Weatherman is also a Director of VitalCom Inc., Uroquest Medical
Corporation and several privately held health care companies.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE ELECTION
OF THE NOMINEES NAMED ABOVE.
Executive Officers
In addition to Mr. Treace, the following persons serve as executive
officers of the Company: F. Barry Bays, Thomas E. Timbie, John R. Treace, R.
Glen Coleman, Guy K. Williamson, Fred B. Dinger, III, Dan H. Treace, Mark J.
Fletcher and Gerard J. Bussell. Their respective ages, positions with the
Company and business experience during the past five years are set forth below.
The Company's executive officers serve at the pleasure of the Board of
Directors.
F. Barry Bays, 50, has been Senior Vice President, Operations and Chief
Operating Officer of the Company since April 1996. From 1993 to April 1996, Mr.
Bays served as Vice President and Chief Operating Officer and a Director of
TreBay. From 1990 to 1993, Mr. Bays served as Executive Vice President and Chief
Operating Officer of Linvatec. From 1981 to 1990, Mr. Bays served as Executive
Vice President and Chief Operating Officer of Concept.
Thomas E. Timbie, 39, has been Vice President, Finance and Chief
Financial Officer of the Company since April 1996. From 1994 to April 1996, Mr.
Timbie served as Vice President and Chief Financial Officer of TreBay. From 1990
to 1994, Mr. Timbie held financial management positions at Linvatec, including
Senior Director, Working Capital from 1992 to 1994 and Assistant Controller from
1990 to 1992. From 1987 to 1990, Mr. Timbie served as Director, Financial
Accounting and Reporting of Concept.
John R. Treace, 52, has been Vice President, U.S. Sales of the Company
since April 1996. From 1995 to April 1996, Mr. Treace served as Vice President,
Sales and Marketing of TreBay. Prior to joining TreBay,
3
<PAGE>
Mr. Treace served in a variety of positions at Richards Medical
Company. His positions at Richards Medical Company included Product Manager,
Director of Marketing and Sales, Group Vice President of Marketing and Sales and
Sales Distributor. Mr. Treace is the brother of James T. Treace and Dan H.
Treace.
R. Glen Coleman, 42, has been Vice President, Marketing of the Company
since August 1996. From January 1983 to August 1996, Mr. Coleman held several
management positions at Linvatec, including Vice President, Global Marketing
from June 1996 to July 1996, Vice President, Sales from October 1993 to June
1996, Vice President and General Manager of its Concept Division from May 1991
to October 1993 and Vice President, Research and Development.
Guy K. Williamson, 42, has been Vice President, International of the
Company and President, Xomed International, Inc. since July 1996. From January
1988 to June 1996, Mr. Williamson held various positions within the
Bristol-Myers Squibb Medical Device Group, including Vice President, Zimmer
International from January 1994 to June 1996, General Manager, China and Hong
Kong from February 1992 to December 1993 and Vice President, Marketing and
International Administration, Linvatec from January 1988 to January 1992.
Fred B. Dinger, III, 35, has been Vice President, Research and
Development of the Company since May 1996. From 1992 to 1996, Mr. Dinger held
several positions with Linvatec, including Vice President, Research and
Development from 1994 to 1996, Director, New Product Development from 1993 to
1994 and Manager, Power Systems Development from 1992 to 1993. From 1984 to
1992, Mr. Dinger was Engineering Section Supervisor at Honeywell Incorporated.
Dan H. Treace, 48, has been Vice President, Regulatory Affairs and
Quality Assurance of the Company since May 1996. From 1994 to April 1996, Mr.
Treace served as Vice President and Quality Manager of TreBay. From 1989 to
1994, Mr. Treace served as Vice President, Technical Affairs of Xomed-Treace,
Inc. ("Xomed-Treace") which was acquired by the Company in 1994. From 1982 to
1989, Mr. Treace was President of Treace Medical, Inc., a microsurgical ENT
medical device company that he founded in 1982 and that was acquired by
Bristol-Myers Squibb in 1989 and merged with the business of Xomed, Inc. to form
Xomed-Treace, Inc. Mr. Treace is the brother of James T. Treace and John R.
Treace.
Mark J. Fletcher, 40, has been Vice President of the Company and
President of Ophthalmic Products since July 1996. From April 1996 to July 1996,
Mr. Fletcher served as Vice President, U.S. Marketing of the Company and from
1994 to April 1996, he served as Vice President, Sales and Marketing of the
Company. From 1988 to 1994, Mr. Fletcher held several senior management
positions with Stryker Corporation, a medical device company, including
Executive Vice President, Sales and Marketing from 1993 to 1994, Vice President
and General Manager, Stryker Medical, the Netherlands from 1992 to 1993, and
Vice President, Sales, Medical Division from 1990 to 1992.
Gerard J. Bussell, 48, has been Vice President of Operations of the
Company since March 1996 and from 1993 to March 1996 was Director of
Manufacturing Operations and Director of Manufacturing of the Company. Prior to
joining the Company, Mr. Bussell served in senior management positions with
Allergan, Inc., an ophthalmic products company, including Senior Director,
Worldwide Materials, and Managing Director.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth, as of March 12, 1997 (except as
otherwise noted), certain information regarding the beneficial ownership of
Common Stock by (i) each Director of the Company, (ii) each person who is known
to the Company to own beneficially more than 5% of the Common Stock, (iii) each
executive officer named in the Summary Compensation Table and (iv) all current
executive officers and Directors of the Company as a group. Such information is
based, in part, upon information provided by such persons.
4
<PAGE>
Beneficial Ownership
-----------------------------
Name Number (1) Percent
- ---- ------------ ---------
Warburg, Pincus Investors, L.P. (2) 3,296,393 44.9%
466 Lexington Avenue
New York, New York 10017
Kingdon Capital Management Corporation (3) 400,000 5.5
152 West 57th Street
New York, New York 10019
Stein Roe & Farnham Incorporated (4) 384,400 5.2
One South Wacker Drive
Chicago, Illinois 60606
James T. Treace (5) 169,517 2.3
F. Barry Bays (6) 101,883 1.4
Mark J. Fletcher (7) 12,500 *
John R. Treace (8) 16,477 *
Gerard J. Bussell (9) 3,000 *
Richard B. Emmitt (10) 274,709 3.7
Paul H. Klingenstein (11) 306,236 4.2
William R. Miller 5,500 *
Rodman W. Moorhead, III (12) 3,296,393 44.9
James E. Thomas (12) 3,296,393 44.9
Elizabeth H. Weatherman (12) 3,296,393 44.9
Mark K. Adams (13) -- --
All current Directors and Executive Officers
as a group (16 persons) (14) 4,221,543 56.9
- --------------------------
* Less than 1%.
(1) Except as otherwise indicated, the persons in this table have sole
voting and investment power with respect to all shares of Common Stock
shown as beneficially owned by them, subject to community property laws
where applicable and subject to the information contained in the
footnotes to this table. Amounts shown for each stockholder include all
shares of Common Stock subject to stock options exercisable within 60
days of March 12, 1997. Shares not outstanding but deemed beneficially
owned by virtue of the right of a person or group to acquire them
within 60 days are treated as outstanding only for purposes of
determining the number of and percent owned by such person or group.
(2) The sole general partner of Warburg, Pincus Investors, L.P. ("Warburg")
is Warburg, Pincus & Co., a New York general partnership ("WP"). EMW
LLC, a New York limited liability company, manages Warburg. The members
of EMW LLC are substantially the same as the partners of WP. Lionel I.
Pincus is the managing partner of WP and the managing member of EMW LLC
and may be deemed to control both WP and EMW LLC. WP, as the sole
general partner of Warburg, has a 20% interest in the profits of
Warburg. Messrs. Moorhead and Thomas and Ms. Weatherman are each a
Director of the Company, a Managing Director and member of EMW LLC and
a general partner of WP. As such, Messrs. Moorhead and Thomas and Ms.
Weatherman may be deemed to have an indirect pecuniary interest
5
<PAGE>
(within the meaning of Rule 16a-1 under the Securities Exchange Act of
1934 (the "Exchange Act")) in an indeterminate portion of the shares
beneficially owned by Warburg and WP. See Note 12 below.
(3) As reflected as beneficially owned at January 21, 1997 in a Statement
on Schedule 13D under the Exchange Act filed with the Securities and
Exchange Commission (the "SEC") on January 21, 1997.
(4) As reflected as beneficially owned at December 31, 1996 in a Statement
on Schedule 13G under the Exchange Act filed with the SEC on February
12, 1997.
(5) Includes 20,416 shares of Common Stock which may be acquired pursuant
to stock options exercisable within 60 days of March 12, 1997. Mr.
Treace has pledged 101,460 shares of Common Stock to Warburg to secure
repayment of a loan used to purchase such shares. As of March 12, 1997,
a principal balance of $1,142,000 was outstanding under the loan. The
loan bears interest at an annual rate of 7% and matures on April 16,
2001.
(6) Includes 15,916 shares of Common Stock which may be acquired pursuant
to stock options exercisable within 60 days of March 12, 1997. Mr. Bays
has pledged 58,414 shares of Common Stock to Warburg to secure
repayment of a loan used to purchase such shares. As of March 12, 1997,
a principal balance of $586,000 was outstanding under the loan. The
loan bears interest at an annual rate of 7% and matures on April 16,
2001.
(7) Includes 12,500 shares of Common Stock which may be acquired pursuant
to stock options exercisable within 60 days of March 12, 1997.
(8) Includes 8,500 shares of Common Stock which may be acquired pursuant to
stock options exercisable within 60 days of March 12, 1997.
(9) Shares of Common Stock which may be acquired pursuant to stock options
exercisable within 60 days of March 12, 1997.
(10) As of January 31, 1997, (i) Vertical Fund Associates, L.P. ("Vertical
Fund") is the direct owner of 222,709 shares of Common Stock and (ii)
Vertical Life Sciences, L.P. ("Vertical Life") is the direct owner of
52,000 shares of Common Stock. The sole general partner of each of
Vertical Fund and Vertical Life is The Vertical Group, L.P. ("VG"). Mr.
Emmitt, a Director of the Company, is a general partner of VG. As such,
Mr. Emmitt may be deemed to have an indirect pecuniary interest (within
the meaning of Rule 16a-1 under the Exchange Act) in an indeterminate
portion of the securities of the Company beneficially owned by VG,
Vertical Fund and Vertical Life. Mr. Emmitt disclaims beneficial
ownership of these securities within the meaning of Rule 13d-3 under
the Exchange Act, except to the extent of his indirect pecuniary
interest.
(11) Includes only shares held by Accel IV L.P., Accel Keiretsu L.P., Accel
Investors '94 L.P. and Prosper Partners (collectively, the "Funds").
Mr. Klingenstein is a (i) general partner of the general partner of
Accel IV L.P.; (ii) an officer of the general partner of Accel Keiretsu
L.P.; (iii) a general partner of Accel Investors '94 L.P.; and (iv)
attorney-in-fact for Prosper Partners. As such, Mr. Klingenstein may be
deemed to have an indirect pecuniary interest (within the meaning of
Rule 16a-1 of the Exchange Act) in an indeterminate portion of the
shares beneficially held by the Funds. Mr. Klingenstein disclaims
beneficial ownership of the shares held by the Funds.
(12) All of the shares of Common Stock indicated as owned by Messrs.
Moorhead and Thomas and Ms. Weatherman are owned directly by Warburg
and are included because of Messrs. Moorhead and Thomas' and Ms.
Weatherman's affiliation with Warburg. Messrs. Moorhead and Ms.
Weatherman disclaim "beneficial ownership" of these shares within the
meaning of Rule 13d-3 under the Exchange Act, except to the extent of
their indirect pecuniary interest. See Note 1.
6
<PAGE>
(13) Mr. Adams' last day of employment with the Company was May 20, 1996.
Based solely upon review of the Company's stockholders of record.
(14) Includes an aggregate of 82,582 shares of Common Stock which may be
acquired within 60 days of March 12, 1997.
EXECUTIVE COMPENSATION
The following table sets forth information for the periods indicated
concerning compensation of (i) the Company's current and former Chief Executive
Officers and (ii) the four other most highly compensated individuals who were
serving as executive officers at the end of fiscal 1996 (collectively, the
"Named Executive Officers").
Summary Compensation Table
Long-term
Compensation
Annual Compensation (Awards)
-----------------------------------------
Other Securities All
Annual Underlying Other
Name and Compen- Options Compen-
Principal Position Year Salary($) Bonus($) sation($) (#) sation($)
- ------------------ ---- --------- -------- --------- ------- ---------
James T. Treace (1) 1996 $153,039 $27,600 (2) 77,333 $2,300(3)
President, Chief 1995 -- -- -- -- --
Executive Officer and
Chairman of the
Board of Directors
Mark K. Adams 1996 79,950 -- $16,074(4) 20,000 505,277(5)
President and Chief 1995 200,525 58,890 37,104(6) -- 2,345(3)
Executive Officer (7)
Mark J. Fletcher 1996 149,615 38,502 -- 10,000 2,671(3)
Vice President, Solan 1995 140,000 4,200 17,224(8) -- --
Ophthalmic Products
F. Barry Bays (9) 1996 116,442 21,000 22,094(10) 52,833 1,519(3)
Senior Vice President 1995 -- -- -- -- --
and Chief Operating
Officer
John R. Treace (11) 1996 94,039 18,360 18,539(12) 30,000 --
Vice President, U.S. 1995 -- -- -- -- --
Sales
Gerard J. Bussell 1996 107,614 7,740 -- 6,000 2,428(3)
Vice President, 1995 94,289 13,759 -- -- 2,074(3)
Operations
- ---------------
(1) Mr. Treace has been President, Chief Executive Officer and Chairman of
the Board of Directors of the Company since April 1996.
(2) Other annual compensation in the form of perquisites and other personal
benefits has been omitted because the aggregate amount of such
perquisites and other personal benefits was less than $50,000 and
constituted less than 10% of the executive's total annual salary and
bonus.
7
<PAGE>
(3) Represents a matching contribution by the Company to the Company's
401(k) Plan for the benefit of the executive.
(4) Represents $12,500 paid to Mr. Adams as a housing allowance and $3,574
paid to Mr. Adams as a car allowance.
(5) Represents $504,076 in payments pursuant to a separation agreement with
Mr. Adams and a matching contribution of $1,201 made by the Company to
the Company's 401(k) Plan for the benefit of Mr. Adams. See
"Employment Agreements and Severance Agreement."
(6) Represents $30,000 paid to Mr. Adams as a housing allowance and $7,104
paid to Mr. Adams as a car allowance.
(7) Mr. Adams' last day of employment with the Company was May 20, 1996.
(8) Represents a reimbursement of Mr. Fletcher's moving expenses.
(9) Mr. Bays has been Senior Vice President, Operations and Chief Operating
Officer of the Company since April 1996.
(10) Represents reimbursement of relocation expenses of $15,900 and car
allowance payments of $6,194.
(11) Mr. Treace has been Vice President, U.S. Sales of the Company since
April 1996.
(12) Represents reimbursement of relocation expenses.
The following table summarizes the number of shares and the terms of
stock options granted to the Named Executive Officers in 1996:
<TABLE>
<CAPTION>
Option Grants During Year Ended December 31, 1996
Potential Realizable
Value at Assumed
Number of % of Total Annual Rates of Stock
Securities Options Price Appreciation for
Underlying Granted to Option Term($)(1)(2)
Options Employees in Exercise Price Expiration ---------------------------
Name Granted(#) Fiscal Year ($/Share) Date 5% 10%
- --------------- ---------- ----------- -------------- ----------- ----------- ----------
<S> <C> <C> <C> <C> <C> <C>
James T. Treace 4,333 1.0% $ 9.36 12/15/04 $ 93,840 $ 154,532
73,000 17.3 10.65 4/16/01 1,178,658 1,692,213
Mark K. Adams 20,000 4.7 9.58 1/01/01 344,320 485,020
Mark J. Fletcher 10,000 2.4 9.58 1/01/01 172,160 242,510
F. Barry Bays 10,833 2.6 9.36 12/15/04 234,610 386,348
42,000 10.0 10.65 4/16/01 678,132 973,602
John R. Treace 6,500 1.5 9.36 12/15/04 140,771 231,816
8,000 1.9 10.65 4/16/01 129,168 185,448
15,500 3.7 10.65(3) 6/14/01 250,263 359,306
Gerard J. Bussell 6,000 1.4 9.58 1/01/01 103,296 145,506
</TABLE>
(1) All options vest annually in 25% increments, commencing on the first
anniversary of the date of grant.
(2) The potential realizable value is calculated based on the term of the
option at its time of grant and is calculated by assuming that the
stock price on the date of grant appreciates at the indicated annual
rate compounded annually for the entire term of the option and that the
option is exercised and sold on the last day of its term for the
appreciated price. At the time the options were granted, there was no
public
8
<PAGE>
trading market for the Common Stock. In order to calculate the
potential realizable value at assumed annual rates of stock
appreciation for the option term, the initial public offering price of
$21.00 per share was used. The 5% and 10% assumed rates of appreciation
are derived from the rules of the SEC and do not represent the
Company's estimate or projection of the future market price of the
Common Stock.
(3) The Company has determined for accounting purposes that the fair market
value of the Common Stock on the date of grant, June 14, 1996, was
$13.15 per share. Accordingly, the potential realizable value, assuming
0% appreciation, would be $38,750.
<TABLE>
<CAPTION>
Aggregated 1996 Option Exercises and Fiscal Year-End Option Values
Number of Securities Value of Unexercised
Underlying Options at In-the-Money Options at
Shares December 31, 1996(#) December 31, 1996($)(1)
Acquired on ---------------------------- ---------------------------
Name Exercise (#) Value Realized($) Exercisable Unexercisable Exercisable Unexercisable
- ------------------------ ------------ ----------------- ----------- ------------- ----------- -------------
<S> <C> <C> <C> <C> <C> <C>
James T. Treace -- -- 2,166 75,167 $ 23,046 $705,607
Mark K. Adams -- -- 60,000 -- 625,200 --
Mark J. Fletcher -- -- 10,000 20,000 104,200 208,400
F. Barry Bays -- -- 5,416 47,417 57,626 450,337
John R. Treace -- -- 6,500 23,500 69,160 219,725
Gerard J. Bussell -- -- 1,000 7,000 10,420 72,940
- ----------------
</TABLE>
(1) Based on a value of $20.00 per share, the closing price for the Common
Stock on December 31, 1996.
Employment Agreements and Severance Agreement
In connection with its April 1996 acquisition of TreBay, the Company
executed employment agreements with James T. Treace and F. Barry Bays. The
Company agreed to employ Mr. Treace as President, Chairman of the Board of
Directors and Chief Executive Officer at an annual salary of $230,000 and Mr.
Bays as Senior Vice President of Operations and Chief Operating Officer at an
annual salary of $175,000. Under the terms of the employment agreements, the
Compensation Committee reviews the compensation of Messrs. Treace and Bays at
least once each year, and may award such bonuses and effect such increases in
base salary as it shall determine. In addition, Messrs. Treace and Bays are
eligible for the Key Executive Bonus Program adopted by the Company, which
program provides for a bonus in an amount up to and at the 50% level of an
employee's salary upon attainment of the bonus criteria. The employment
agreements have an initial term of three years, and may be extended upon good
faith negotiations between the parties, which negotiations shall begin not later
than 90 days prior to the expiration of the stated term of the agreement.
The agreements entitle these executive officers to participate in such
fringe benefits as shall be generally provided to the executives of the Company,
including medical insurance and retirement programs which may be adopted from
time to time by the Company. In addition, in connection with entering into the
employment agreements in April 1996, the Company granted to Messrs. Treace and
Bays 73,000 and 42,000 stock options, respectively, under the Stock Option Plan,
and each of Messrs. Treace and Bays are eligible for additional grants of stock
options as target bonuses pursuant to corporate performance objectives
established by the Board of Directors' Compensation Committee. The Compensation
Committee will review each executive officer's compensation and award such
bonuses or make such increases to the annual salary as the Compensation
Committee, in its sole discretion, determines are merited.
The employment agreements contain covenants prohibiting the improper
disclosure and use of any of the Company's and its predecessors' trade secrets,
know-how and proprietary processes, as well as provisions assigning to the
Company all inventions made or conceived by the executive officer during his
employment with the Company. Each executive officer agreed with the Company that
until twelve months after the termination of his employment with the Company he
would not (whether as an officer, Director, owner, employee, partner or
10
<PAGE>
other direct or indirect participant) engage in any Competitive Business
(defined as the manufacturing, supplying, producing, selling, distributing or
providing for sale of (i) any product, device or instrument manufactured from or
using polyvinal acetal (PVAc) material or technology or (ii) any eye, ear, nose
or throat product, device or instrument (x) of a type manufactured or sold by
the Company or its subsidiaries or (y) in clinical development sponsored by the
Company or its subsidiaries, in each case, as of the date of termination of
employment).
The Company may terminate the employment of the executive officers
under the employment agreements (i) upon 30 days' notice if the employee becomes
physically or mentally incapacitated or is injured so that he is unable to
perform the services required of him and such inability to perform continues for
a period in excess of six months and is continuing at the time of such notice;
(ii) for cause upon notice of such termination to the employee; or (iii) without
cause upon 30 days' notice of such termination to the employee. If an employment
agreement is terminated pursuant to (i) above, the executive officer shall
receive salary continuation pay from the date of such termination until April
16, 1999, reduced by applicable payroll taxes and amounts received by the
executive officer under any Company-maintained disability insurance policy or
plan under Social Security or similar laws. If an employment agreement is
terminated pursuant to (ii) above, the executive officer shall receive no salary
continuation pay or severance pay. If an employment agreement is terminated
pursuant to (iii) above, the executive officer shall receive salary continuation
pay for a period of twelve months from and after the date of such termination.
On May 10, 1996, the Company entered into a Separation Agreement with
Mark K. Adams (the "Separation Agreement"). Pursuant to the terms of the
Separation Agreement: (i) all options received by Mr. Adams under the Stock
Option Plan became fully vested; (ii) the Company agreed to provide to Mr. Adams
an allowance for outplacement services; (iii) the Company paid Mr. Adams a
severance payment of $359,532; (iv) the Company's loan to Mr. Adams in the
amount of $300,007 was satisfied in full in exchange for his surrender of 9,563
shares of Series A Convertible Preferred Stock, par value $1.00 per share, of
the Company and 2,074 shares of Series C Redeemable Preferred Stock, par value
$1.00 per share, of the Company held by him; and (v) the Company agreed to make
monthly severance payments to Mr. Adams at a rate of $175,000 per year for two
years, with the first year's payment guaranteed and payments in the second year
payable only until such time as he obtains full time employment elsewhere. Mr.
Adams has obtained full time employment and therefore the Company is not
obligated to make severance payments during the second year. Mr. Adams has also
agreed to provide consulting services to the Company for a period of two years
for no additional consideration. In addition, Mr. Adams has agreed with the
Company that, until May 10, 1998, he will not (whether as an officer, Director,
owner, employee, partner or other direct or indirect participant) engage in any
Competitive Business (defined in substantially the same manner as described
above with respect to the employment agreements of James T. Treace and F. Barry
Bays). During this same two-year period, Mr. Adams has agreed that he will not,
directly or indirectly, employ or solicit for employment any person then
employed by the Company. Mr. Adams also has agreed that he only will use
confidential information with respect to the Company for the benefit of the
Company and only disclose this information to others with the Company's prior
approval.
Meetings of the Board of Directors
The Board of Directors met five times during 1996. Each of the
Directors serving on the Board of Directors in 1996 attended at least 75% of all
meetings of the Board of Directors and of each committee on which such Director
served as a member.
Committees of the Board of Directors
The Board of Directors has, as standing committees, an Audit Committee
and a Compensation Committee. The Board of Directors does not have a Nominating
Committee.
11
<PAGE>
Audit Committee. The Audit Committee consists of Messrs. Thomas and
Miller and Ms. Weatherman. The Audit Committee reviews the results and scope of
the annual audit of the Company's financial statements conducted by the
Company's independent accountants, the scope of other services provided by the
Company's independent accountants, proposed changes in the Company's financial
and accounting standards and principles, and the Company's policies and
procedures with respect to its internal accounting, auditing and financial
controls and makes recommendations to the Board of Directors on the engagement
of the independent accountants, as well as other matters which may come before
the Audit Committee or at the direction of the Board of Directors. The Audit
Committee met one time in 1996.
Compensation Committee. The Compensation Committee consists of Messrs.
Emmitt and Miller and Ms. Weatherman. The Compensation Committee provides
recommendations concerning salaries and incentive compensation for employees of,
and consultants to, the Company and administers the Stock Option Plan and the
Company's 401(k) and Profit Sharing Plan. The Compensation Committee met five
times in 1996.
Compensation of Directors
William R. Miller receives from the Company $1,000 in directors' fees
per meeting attended. No other member of the Board of Directors currently
receives directors' fees from the Company. The Company is obligated to reimburse
its Board members for all reasonable expenses incurred in connection with their
attendance at directors' meetings.
On February 5, 1997, the Compensation Committee granted William R.
Miller options to purchase 5,000 shares of Common Stock at an exercise price of
$15.0625 per share. The options vest over a four-year period and are subject to
the same terms and conditions as options previously granted under the Stock
Option Plan as set forth in the Company's standard form of Stock Option
Agreement.
Compensation Committee Report on Executive Compensation
Compensation Philosophy. The Compensation Committee generally follows
several guidelines to arrive at its recommendations to the Board of Directors
concerning the compensation of the Company's executive officers. The Company's
executive compensation program is designed to (i) attract and retain executive
officers who contribute to the long-term success of the Company, (ii) motivate
executive officers to achieve strategic business objectives and reward them for
their achievement, and (iii) fairly compensate executive officers based on their
corporate and individual performance and responsibilities.
To date, the primary elements of the Company's compensation program for
its executive officers have been (i) an annual compensation component consisting
of base salary and bonus and (ii) a long-term compensation component consisting
of stock options granted under the Stock Option Plan.
Annual Compensation. The Compensation Committee has generally targeted
annual salary and bonus levels to be competitive with those paid to executives
at other companies that have similar operating dynamics. Base salaries are
determined by evaluating the responsibilities associated with the position being
evaluated and the individual's overall level of experience. Annual salary
adjustments are determined by giving consideration to the Company's performance
and the individual's contribution to that performance.
Each of the executive officers' annual bonus is determined based on the
achievement of certain objectives agreed-upon with the executive. In determining
these objectives, the Compensation Committee considers the Company's performance
and the individual's contribution to that performance. Corporate performance is
measured by various quantitative and qualitative factors. However, the
Compensation Committee believes that, in accordance with its exercise of sound
business judgment, the determination of annual salary and bonus levels is
inherently subjective and must include a review of all relevant information,
with no predetermined weight given to any of the factors considered.
12
<PAGE>
Messrs. James T. Treace and Bays are the only executive officers
currently party to employment agreements with the Company. These agreements
establish the annual base salaries for Messrs. Treace and Bays. The annual base
salaries for Messrs. Timbie, John R. Treace, Coleman, Williamson, Dinger, Dan H.
Treace, Fletcher and Bussell were, and future salary increases for the executive
officers will be, based on the considerations noted above.
Key Executive Bonus Program. The Company maintains a Key Executive
Bonus Program in which key management personnel are eligible to participate. The
plan allows participants to earn bonuses up to stated percentages of their base
salary. For 1996, the percentages were as follows: 50% for the President and
Senior Vice President, 30-40% for Vice Presidents, 25% for directors and
regional sales managers, 25% for international managers, 20% for first level
managers and 10% for second level managers and key employees. The bonuses are
paid based on the Company's achievement of operating results, including sales,
profitability and asset management goals. During 1996, a total of 47 key
employees participated in the bonus plan. The Company presently intends to
continue the bonus plan for 1997 and future years.
Long-Term Compensation. In order to align stockholder and executive
officer interests, the long-term component of the Company's executive
compensation program involves stock option awards whose value is directly
related to the value of the Common Stock. These stock options are granted by the
Compensation Committee pursuant to the Stock Option Plan. Stock option awards to
Messrs. James T. Treace and Bays are based upon certain corporate performance
objectives established by the Compensation Committee. Other individuals to whom
stock options awards are to be granted and the amount of Common Stock related to
such awards are determined solely at the discretion of the Compensation
Committee. Because individual stock option award levels will be based on a
subjective evaluation of each individual's overall past and expected future
contribution, no specific formula is used to determine such awards for any
executive other than Messrs. James T. Treace and Bays.
Chief Executive Officer Compensation for 1996. Under the terms of the
employment agreement with Mr. James T. Treace, the Compensation Committee
reviews Mr. Treace's compensation at least once each year, and will award such
bonuses and effect such increases in base salary as it shall determine. The
determination by the Compensation Committee with respect to Mr. Treace's
compensation for 1996 was based on the considerations noted above.
COMPENSATION COMMITTEE
Richard B. Emmitt
William R. Miller
Elizabeth H. Weatherman
Comparative Stock Price Performance Graph
The graph below compares the total cumulative return of the Common
Stock from October 11, 1996 (the date trading of the Common Stock commenced) to
December 31, 1996, to the performance of the S&P Midcap 400 Index and the S&P
Health Care (Medical Products and Supplies) Index during such period. The graph
assumes that dividends were reinvested and is based on an investment of $100 on
October 11, 1996 in each of the Common Stock, the stocks comprising the S&P
Midcap 400 Index and the stocks comprising the S&P Health Care (Medical Products
and Supplies) Index.
13
<PAGE>
COMPARISON OF 2 MONTH CUMULATIVE TOTAL RETURN
Among Xomed Surgical Products, Inc.,
The S&P Midcap 400 Index
and
The S&P Health Care (Medical Products and Supplies) Index
<TABLE>
[PERFORMANCE GRAPH APPEARS HERE]
Cumulative Total Return
-----------------------
10/11/96 12/31/96
-------- --------
<S> <C> <C>
Xomed Surgical Products, Inc. $100 $95
S&P Midcap 400 Index $100 $106
S&P Health Care (Medical Products and Supplies) Index $100 $101
</TABLE>
Compensation Committee Interlocks and Insider Participation
No officer or employee of the Company currently serves as a member of
the Compensation Committee.
Certain Transactions
The following is a summary of certain transactions among the Company
and its Directors, executive officers and principal stockholders:
Stockholders Agreement. Under a stockholders agreement among
the Company and substantially all of its then-existing stockholders,
executed in connection with the acquisition of TreBay, so long as Warburg
owns 40% or more of the total number of outstanding shares of Common Stock,
Warburg will have the right to designate three persons to be appointed or
nominated for election to the Board of Directors. If at any time Warburg owns
less than 40%, but 20% or more, of the total number of outstanding shares of
Common Stock, Warburg will have the right to designate two persons to be
appointed or nominated for election to the Board of Directors. If at any
time Warburg owns less than 20%, but 10% or more, of the total number of
outstanding shares of Common Stock, Warburg will have the right to designate
one person to be appointed or nominated for election to the Board of
Directors. Warburg currently has under the stockholders agreement the
right to designate three persons to be appointed or nominated to the Board of
Directors. In addition, the stockholders agreement provides each
stockholder that is a party thereto with certain rights to inspect the
Company's properties and its books and records and to discuss its affairs
with management so long as the stockholder holds at least 2% of the
outstanding Common Stock.
TreBay Loan. On November 7, 1995, TreBay loaned $883,000 to James T.
Treace, its President and Chief Executive Officer. Following the Company's
acquisition of TreBay in April 1996, Mr. Treace became the Company's President
and Chief Executive Officer. As of March 12, 1997, a principal balance of
$724,000 was outstanding under the loan. The loan is payable on demand at any
time following November 7, 2000 and matures on November 7, 2002. Interest
accrues on the loan at an annual rate of 10% and is payable, at Mr. Treace's
election, upon each anniversary of the loan or its maturity. The loan is secured
by a pledge of 44,460 shares of Common Stock.
14
<PAGE>
Exchange of Series C Preferred Stock. Pursuant to an agreement among
the Company and certain of its stockholders, upon consummation of the initial
public offering of Common Stock in October 1996, (i) 238,300 shares of Series C
Redeemable Preferred Stock, par value $1.00 per share, of the Company (the
"Series C Preferred Stock") were redeemed by the Company and (ii) the remaining
60,126 shares of Series C Preferred Stock not so redeemed were exchanged for
300,354 shares of Common Stock.
Registration Rights. In connection both with the formation of the
Company and its acquisition of TreBay, the Company granted certain rights with
respect to the registration of approximately 4,258,554 shares of Common Stock
currently held by certain stockholders (the "Investors" and such shares the
"Registrable Securities"). Such registration rights also extend to any capital
stock of the Company issued as a dividend or other distribution with respect to,
or in exchange for or in replacement of, the shares of Common Stock referred to
above and any additional shares of Common Stock which any of the Investors may
thereafter acquire. Certain of the Investors hold options to purchase an
aggregate of 303,166 shares of Common Stock. The shares obtained upon the
exercise of such options will also be Registrable Securities. A holder or
holders of the Registrable Securities (each, a "Holder") who are a Holder or
Holders of more than 20% of the then outstanding Registrable Securities (each,
an "Initiating Holder") are entitled to request that the Company file a
registration statement under the Securities Act covering the sale of some or all
of the Registrable Securities owned by such holders, subject to certain
conditions. The Company is required to effect no more than two such
registrations (three if the prior registrations did not include Warburg as an
Initiating Holder). The Company is not required to effect any such registration
if the anticipated aggregate public offering price of the shares of Common Stock
proposed to be registered is less than $5.0 million. If officers or directors of
the Company holding other securities of the Company request inclusion in any
such registration, or if holders of securities of the Company other than
Registrable Securities who are entitled, by contract with the Company or
otherwise, to have securities included in such a registration (the "Other
Shareholders") request such inclusion, the Holders will offer to include the
securities of such officers, directors and Other Shareholders in any
underwriting involved in such registration, provided, among other conditions,
that the underwriter representative of any such offering has the right, subject
to certain conditions, to limit the number of Registrable Securities included in
the registration. In addition, in the event that the Company proposes to
register any of its securities under the Securities Act of 1933, as amended (the
"Securities Act") (other than registrations relating solely to employee benefit
plans or pursuant to Rule 145 or on a form which does not permit secondary sales
or does not include substantially the same information as would be required to
be included in a registration statement covering the sale of Registrable
Securities), either for its own account or for the account of other security
holders or holders exercising their respective demand registration rights,
holders of Registrable Securities may require the Company to include all or a
portion of their Registrable Securities in the registration and in any
underwriting involved therein, provided, among other conditions, that the
underwriter representative of any such offering has the right, subject to
certain conditions, to limit the number of Registrable Securities included in
the registration. Further, once the Company is qualified to use Form S-3 to
register securities under the Securities Act, the holders of Registrable
Securities shall have the right to request three registrations on Form S-3 to
register all or a portion of such shares under the Securities Act, subject to
certain conditions. In general, all fees, costs and expenses of such
registrations (other than underwriting discounts and selling commissions
applicable to sales of the Registrable Securities and all fees and disbursements
of counsel for each of the Holders) will be borne by the Company.
15
<PAGE>
PROPOSAL TWO
AMENDMENT OF STOCK OPTION PLAN TO
INCREASE SHARES OF COMMON STOCK RESERVED FOR ISSUANCE
Amendments
Options to purchase an aggregate of 778,000 shares of Common Stock are
currently authorized under the Stock Option Plan. As of March 12, 1997, a total
of 9,534 shares of Common Stock remained available for future grant under the
Stock Option Plan. In order to provide for sufficient shares of Common Stock for
future grants, the Board of Directors has amended the Stock Option Plan, subject
to stockholder approval, to provide that the number of shares of Common Stock
reserved for issuance under the Stock Option Plan be increased by 300,000 shares
from 778,000 to 1,078,000. The Board of Directors has also amended the Stock
Option Plan, subject to stockholder approval, to comply with Section 162(m) of
the Internal Revenue Code of 1986, as amended (the "Code"), by providing that
the number of shares of Common Stock with respect to which options may be
granted to any single optionee during any calendar year shall not exceed 60,000.
In addition, the Board of Directors approved additional, non-substantive
amendments to the Stock Option Plan to reflect the Company's status as a public
company. The Stock Option Plan as so amended is hereby submitted to the
stockholders of the Company for approval.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" THE ADOPTION
OF THE AMENDMENTS TO THE STOCK OPTION PLAN.
A general description of the basic features of the Stock Option Plan is
set forth below. Such description is qualified in its entirety by reference to
the full text of the Stock Option Plan, a copy of which may be obtained without
charge upon written request to Thomas E. Timbie, Secretary of the Company.
On April 15, 1996, the Board of Directors adopted and the stockholders
approved the Stock Option Plan. The Stock Option Plan was subsequently amended
and restated on June 14, 1996 and July 24, 1996 and approved by stockholders on
July 24, 1996. The Stock Option Plan is open to participation by Directors,
officers, consultants, other key employees of the Company or of its subsidiaries
and certain other key persons who the Stock Option Committee (as defined below)
determines shall receive options under the Stock Option Plan.
The Stock Option Plan authorizes: (i) the grant of options to purchase
Common Stock intended to qualify as incentive stock options ("Incentive
Options"), as defined in Section 422 of the Code; and (ii) the grant of options
that do not so qualify ("Non-Statutory Options" and, together with Incentive
Options, "Options"). At present, an aggregate of 778,000 shares of Common Stock
have been reserved for issuance under the Stock Option Plan. As of March 12,
1997, options to purchase an aggregate of 565,766 shares having a weighted
average exercise price of $11.70 per share were outstanding under the Stock
Option Plan, options for 198,700 shares had been exercised under the Stock
Option Plan and options to purchase 9,534 shares were available for grant under
the Stock Option Plan. The Stock Option Plan expires on April 16, 2004. On April
15, 1997, the last reported sale price for the Common Stock on the Nasdaq
National Market was $15.375 per share.
The Stock Option Plan is administered by a committee (the "Stock Option
Committee") appointed by the Board of Directors. The Compensation Committee
serves as the Stock Option Committee. The Stock Option Committee has the sole
authority, in its absolute discretion: (i) to determine which of the eligible
employees of the Company and its subsidiaries shall be granted options; (ii) to
authorize the granting of both Incentive Options and Non-Statutory Options;
(iii) to determine the times when options shall be granted and the number of
shares to be optioned; (iv) to determine the option price of the shares subject
to each option, subject to the limitations described below; (v) to determine the
time or times when each option becomes exercisable, the duration of the exercise
period and any other restrictions on the exercise of options issued under the
Stock
16
<PAGE>
Option Plan; (vi) to prescribe the form or forms of the option agreements under
the Stock Option Plan; (vii) to adopt, amend and rescind such rules and
regulations as, in its opinion, may be advisable in the administration of the
Stock Option Plan; and (viii) to construe and interpret the Stock Option Plan,
the rules and regulations and the option agreements under the Stock Option Plan
and to make all other determinations deemed necessary or advisable for the
administration of the Stock Option Plan. All decisions, determinations and
interpretations of the Stock Option Committee are final and binding on all
optionees.
Incentive Options may be granted only to officers and other key
employees of the Company or its subsidiaries. Non-Statutory Options may be
granted to Directors, consultants, or other key persons who the Stock Option
Committee determines shall receive options under the Stock Option Plan. The
approximate number of officers and other key employees eligible to participate
is 100, and the number of Directors eligible to participate is 7.
No option may be exercised after the date ten years from the date of
grant of such option (five years in the case of Incentive Options of individuals
holding more than ten percent of the total combined voting power of all classes
of stock of the Company or of any parent or subsidiary thereof
("greater-than-ten-percent-stockholders")) (the "Termination Date"). The
exercise price for Non-Statutory Options may not be less than 50% of the fair
market value of the Common Stock on the date of grant. The exercise price for
Incentive Options may not be less than 100% of fair market value of the Common
Stock on the date of grant (110% in the case of a
greater-than-ten-percent-stockholder). The aggregate fair market value
(determined as of the time the option is granted) of the Common Stock with
respect to which any Incentive Options may be exercisable for the first time by
the optionee in any calendar year (under the Stock Option Plan or any other
stock option plan of the Company or any parent or subsidiary thereof) shall not
exceed $100,000.
Options are non-transferable except by will or the laws of descent and
distribution. Generally, unless otherwise provided by the Stock Option
Committee, options granted under the Stock Option Plan terminate upon the
earliest of: (i) the expiration date of the option; (ii) the date of voluntary
termination of the optionee's employment by the optionee; (iii) the date of
termination of the optionee's employment by the Company for cause; (iv) three
months after the date of termination of the optionee's employment by the Company
without cause; (v) one year after the cessation of the optionee's employment by
reason of a disability within the meaning of Section 105(d)(4) of the Code; and
(vi) one year after the death of an optionee prior to the Termination Date and
while employed by the Company or a subsidiary thereof or while entitled to
exercise an option pursuant to (v) above (such option shall be exercisable by
the person to whom the optionee's rights under the option pass by will or the
applicable laws of descent and distribution). For purposes of the Stock Option
Plan, the Company shall have "cause" to terminate an optionee's employment if
the Company has cause to terminate the optionee's employment under any existing
employment agreement between the optionee and the Company or, in the absence of
such an employment agreement, upon (a) determination by the Board of Directors
that the optionee has ceased to perform his duties to the Company (other than as
a result of his incapacity due to physical or mental illness or injury), which
failure amounts to an intentional and extended neglect of his duties to the
Company, (b) the Board of Directors' determination that the optionee has engaged
or is about to engage in conduct materially injurious to the Company or (c) the
optionee having been convicted of a felony. If an option may be exercised during
any period after the termination of an optionee's employment with the Company,
such option may be exercised only to the extent that the optionee was entitled
to exercise such option at the time of such termination.
Payment for shares of Common Stock purchased under an Option must be
made in full upon exercise of the Option by certified or bank cashier's check
payable to the order of the Company, by the surrender or delivery to the Company
of shares of Common Stock held for at least six months, or by any other means
acceptable to the Company and designated by the Stock Option Committee.
The Board of Directors may, without the consent of the Company's
stockholders or optionees under the Stock Option Plan, terminate the Stock
Option Plan at any time or from time to time amend or modify the Stock Option
Plan, provided that no such action adversely affects Options previously granted
without the optionee's consent. The Board of Directors may not amend or modify
the Stock Option Plan, without approval of the
17
<PAGE>
stockholders, to (i) increase the total number of shares of Common Stock which
may be purchased pursuant to Options granted under the Stock Option Plan or (ii)
decrease the minimum Option price.
Federal Income Tax Consequences
The following is a brief discussion of the Federal income tax
consequences of transactions under the Stock Option Plan based on the Code, as
in effect as of the date hereof. The Stock Option Plan is not qualified under
Section 401(a) of the Code. This discussion is not intended to be exhaustive and
does not describe the state or local tax consequences.
Incentive Stock Options. No taxable income is realized by the optionee
upon the grant or exercise of an Incentive Option. If Common Stock is issued to
an optionee pursuant to the exercise of an Incentive Option, and if no
disqualifying disposition of such shares is made by such optionee within two
years after the date of grant or within one year after the transfer of such
shares to such optionee, then (i) upon sale of such shares, any amount realized
in excess of the exercise price will be taxed to such optionee as a long-term
capital gain and any loss sustained will be a long-term capital loss, and (ii)
no deduction will be allowed to the optionee's employer for Federal income tax
purposes.
If the Common Stock acquired upon the exercise of an Incentive Option
is disposed of prior to the expiration of either holding period described above,
generally (i) the optionee will realize ordinary income in the year of
disposition in an amount equal to the excess (if any) of the fair market value
of such shares at exercise (or, if less, the amount realized on the disposition
of such shares) over the exercise price paid for such shares, and (ii) the
optionee's employer will be entitled to deduct such amount for Federal income
tax purposes if the amount represents an ordinary and necessary business
expense. Any further gain (or loss) realized by the optionee will be taxed as
short-term or long-term capital gain (or loss), as the case may be, and will not
result in any deduction by the employer.
Subject to certain exceptions for disability or death, if an Incentive
Option is exercised more than three months following the termination of
employment, the exercise of the option will generally be taxed as the exercise
of a Non-Statutory Option.
For purposes of determining whether an optionee is subject to any
alternative minimum tax liability, an optionee who exercises an Incentive Option
generally would be required to increase his or her alternative minimum taxable
income, and compute the tax basis in the stock so acquired, in the same manner
as if the optionee had exercised a non-qualified stock option. Each optionee is
potentially subject to the alternative minimum tax. In substance, a taxpayer is
required to pay the higher of the optionee's alternative minimum tax liability
or the optionee's "regular" income tax liability. As a result, a taxpayer has to
determine the taxpayer's potential liability under the alternative minimum tax.
Non-Statutory Stock Options. Except as noted below, with respect to
Non-Statutory Options, (i) no income is realized by the optionee at the time the
option is granted; (ii) generally, at exercise, ordinary income is realized by
the optionee in an amount equal to the difference between the exercise price
paid for the shares and the fair market value of the shares on the date of
exercise, and the optionee's employer is generally entitled to a tax deduction
in the same amount subject to applicable tax withholding requirements; and (iii)
at sale, the amount of appreciation (or depreciation) after the date as of which
amounts are includable in income is treated as either short-term or long-term
capital gain (or loss), depending on how long the shares have been held.
Special Rules Applicable to Corporate Insiders. As a result of the
rules under Section 16(b) of the Exchange Act, "insiders" (as defined in the
Exchange Act), depending upon the particular exemption from the provisions of
Section 16(b) utilized, may not receive the same tax treatment as set forth
above with respect to the grant and/or exercise of options. Generally, insiders
will not be subject to taxation until the expiration of any period during which
they are subject to the liability provisions of Section 16(b) of the Exchange
Act with
18
<PAGE>
respect to any particular option. Insiders should check with their individual
tax advisers to ascertain the appropriate tax treatment for any particular
option.
New Plan Benefits
The grant of Options under the Stock Option Plan is entirely within the
discretion of the Stock Option Committee. The Company cannot forecast the extent
of option grants that will be made in the future. Therefore, the Company has
omitted the tabular disclosure of the benefits or amounts allocated under the
Stock Option Plan. Compensation paid and other benefits granted in respect of
the 1996 fiscal year to the Named Executive Officers are set forth in the
Summary Compensation Table.
PROPOSAL THREE
APPOINTMENT OF INDEPENDENT AUDITORS
The Board of Directors has, upon recommendation of the Audit Committee
and subject to ratification by the stockholders, appointed Ernst & Young LLP as
independent auditors to report on the consolidated financial statements of the
Company for the fiscal year ending December 31, 1997, and to perform such other
services as may be required of Ernst & Young LLP. Although stockholder
ratification of the Board of Directors' selection is not required, the Board of
Directors considers it desirable for the stockholders to pass upon the selection
of the independent auditors. If the stockholders disapprove of the selection of
Ernst & Young LLP as independent auditors, the Board of Directors will consider
the selection of other independent auditors. One or more representatives of
Ernst & Young LLP will be present at the Annual Meeting, will have the
opportunity to make a statement if he or she desires to do so and will be
available to respond to appropriate questions.
THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE "FOR" RATIFICATION
OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT AUDITORS FOR 1997.
SECTION 16(a) BENEFICIAL OWNERSHIP
REPORTING COMPLIANCE
Section 16(a) of the Exchange Act requires the Company's executive
officers, Directors and persons who own more than 10% of the Common Stock, to
file with the SEC initial reports of ownership and reports of changes in
ownership of Common Stock. Executive officers, Directors and greater than 10%
stockholders are required by SEC regulation to furnish the Company with copies
of all Section 16(a) forms they file.
To the Company's knowledge, based solely on review of the copies of
such reports furnished to the Company, all Section 16(a) filing requirements
applicable to its executive officers, Directors and greater than 10% beneficial
owners were complied with during the fiscal year ended December 31, 1996.
STOCKHOLDER PROPOSALS -- 1997 ANNUAL MEETING
Any proposals of stockholders of the Company intended to be included in
the Company's proxy statement and form of proxy relating to the Company's next
annual meeting of stockholders must be in writing and received by the Secretary
of the Company at the Company's office at 6743 Southpoint Drive North,
Jacksonville, Florida 32216 no later than December 26, 1997.
OTHER MATTERS
The Board of Directors does not know of any matters other than the
foregoing that will be presented for consideration at the Annual Meeting.
However, if other matters properly come before the Annual Meeting, it is
19
<PAGE>
the intention of the persons named in the enclosed proxy card to take such
action as is in the best interests of the Company and its stockholders.
The entire cost of soliciting proxies from its stockholders will be
borne by the Company. In addition to the use of the mails, proxies may be
solicited by personal interview, telephone or telegram by Directors, officers or
regular employees of the Company, who will not receive additional compensation
for such solicitation but may be reimbursed for reasonable out-of-pocket
expenses incurred in connection therewith. Arrangements may also be made with
brokerage firms and other custodians, nominees and fiduciaries to forward proxy
solicitation materials to the beneficial owners of shares of Common Stock held
of record by such persons, in which case the Company will reimburse such
brokerage firms, custodians, nominees and fiduciaries for reasonable
out-of-pocket expenses incurred by them in connection therewith.
The Company will provide to any stockholder of record and beneficial
owners at the close of business on April 15, 1997, without charge upon written
request to its Secretary at 6743 Southpoint Drive North, Jacksonville, Florida
32216, a copy of the Company's Annual Report on Form 10-K for the fiscal year
ended December 31, 1996.
The principal executive offices of the Company are located at 6743
Southpoint Drive North, Jacksonville, Florida 32216 and the Company's telephone
number is (904) 296-9600.
By order of the Board of Directors,
/s/ Thomas E. Timbie
Thomas E. Timbie
Secretary
20
<PAGE>
XOMED SURGICAL PRODUCTS, INC.
6743 Southpoint Drive North
Jacksonville, Florida 32216
PROXY FOR THE ANNUAL MEETING OF STOCKHOLDERS
at 3:30 p.m., Jacksonville time, on May 28, 1997
The undersigned hereby appoints James T. Treace and Thomas E. Timbie,
and each of them, with full power of substitution, as proxies of the undersigned
to vote all shares of stock which the undersigned is entitled in any capacity to
vote at the above-stated annual meeting, and at any and all adjournments or
postponements thereof (the "Annual Meeting"), on the matters set forth on the
reverse side of this Proxy Card, and, in their discretion, upon all matters
incident to the conduct of the Annual Meeting and upon such other matters as may
properly be brought before the Annual Meeting. This proxy revokes all prior
proxies given by the undersigned.
All properly executed proxies will be voted as directed. If no
instructions are indicated on a properly executed proxy, such proxy will be
voted FOR approval of Proposals 1, 2 and 3. All ABSTAIN votes will be counted in
determining the existence of a quorum at the Annual Meeting, but will have the
same effect as a vote AGAINST Proposals 2 and 3.
THIS PROXY IS SOLICITED ON BEHALF OF
THE BOARD OF DIRECTORS OF XOMED
SURGICAL PRODUCTS, INC.
Receipt of the Notice of Meeting and
the Proxy Statement, dated April 24,
1997 (the " Proxy Statement"), is
hereby acknowledged.
PLEASE SIGN AND DATE ON THE REVERSE
SIDE AND MAIL THIS PROXY CARD PROMPTLY
USING THE ENCLOSED ENVELOPE.
(Continued on reverse side)
<PAGE>
(Continued from reverse side)
THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF
XOMED SURGICAL PRODUCTS, INC.
THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR
PROPOSALS 1, 2 AND 3.
Please mark boxes in blue or black ink.
1. Election of Directors FOR all nominees listed below: [ ]
Nominees: James T. Treace, Richard B. Emmitt, Paul H. Klingenstein, William R.
Miller, Rodman W. Moorhead, III, James E. Thomas and Elizabeth H.
Weatherman
INSTRUCTION: If you wish to withhold authority to vote for any individual
nominee, write that nominee's name on the line provided below:
- --------------------------------------------------------------------------------
<TABLE>
<S> <C>
2. Proposal to approve amendments to the Company's Stock (Joint owners should EACH sign. Please sign EXACTLY as
Option Plan to, among other things, increase the number of your name(s) appears on this card. When signing as attorney,
shares of Common Stock reserved for issuances thereunder by trustee, executor, administrator, guardian or corporate
300,000 shares from 778,000 to 1,078,000. officer, please give your FULL title below.)
FOR [ ] AGAINST [ ] ABSTAIN [ ]
---------------------------------------------------------
(Title or Authority)
3. Proposal to ratify the appointment of Ernst & Young LLP _________________________________________________________
as the independent public auditors of the Company for the (Signature)
fiscal year ending December 31, 1997.
FOR [ ] AGAINST [ ] ABSTAIN [ ] _________________________________________________________
(Signature)
Dated:_______________________, 1997
4. In the discretion of the proxies with respect to
any other matters that may properly come before the
Annual Meeting.
</TABLE>
YOUR VOTE IS IMPORTANT. PLEASE SIGN, DATE AND MAIL THIS PROXY CARD PROMPTLY
USING THE ENCLOSED ENVELOPE.
<PAGE>
APPENDIX
(SEC filing only)
Third Amended and Restated 1996 Stock Option Plan.
<PAGE>
THIRD AMENDED AND RESTATED
XOMED SURGICAL PRODUCTS, INC.
1996 STOCK OPTION PLAN
* * *
ARTICLE I
Purpose
-------
This Third Amended and Restated 1996 Stock Option Plan (the "Plan") is
intended as an incentive and to encourage stock ownership by officers and
certain other key employees of Xomed Surgical Products, Inc. (the "Company") and
its subsidiaries in order to increase their proprietary interest in the
Company's success and to encourage them to remain in the employ of the Company.
The word "Company", when used in the Plan with reference to employment,
shall include subsidiaries of the Company. The word "subsidiary", when used in
the Plan, shall mean any subsidiary of the Company within the meaning of Section
424(f) of the Internal Revenue Code of 1986, as amended (the "Code").
It is intended that certain options granted under this Plan will
qualify as "incentive stock options" under Section 422 of the Code.
ARTICLE II
Administration
--------------
The Plan shall be administered by a Compensation Committee (the
"Committee") appointed by the Board of Directors of the Company (the "Board").
Subject to the provisions of the Plan, the Committee shall have sole authority,
in its absolute discretion: (a) to determine which of the eligible employees of
the Company and its subsidiaries shall be granted options; (b) to authorize the
granting of both incentive stock options and non-qualified options; (c) to
determine the times when options shall be granted and the number of shares to be
optioned; (d) to determine the option price of the shares subject to each
option, which price shall be not less than the minimum specified in ARTICLE V;
(e) to determine the time or times when each option becomes exercisable, the
duration of the exercise period and any other restrictions on the exercise of
options issued hereunder; (f) to accelerate the exercisability of any
outstanding options; (g) to prescribe the form or forms of the option agreements
under the Plan (which forms shall be consistent with the terms of the Plan but
need not be identical); (h) to adopt, amend and rescind such rules and
regulations as, in its opinion, may be advisable
<PAGE>
in the administration of the Plan; and (i) to construe and interpret the Plan,
the rules and regulations and the option agreements under the Plan and to make
all other determinations deemed necessary or advisable for the administration of
the Plan. All decisions, determinations and interpretations of the Committee
shall be final and binding on all optionees.
ARTICLE III
Stock
-----
The stock to be optioned under the Plan shall be shares of authorized
but unissued Common Stock of the Company, $.01 par value, or previously issued
shares of Common Stock reacquired by the Company (the "Stock"). Under the Plan,
the total number of shares of Stock which may be purchased pursuant to options
granted hereunder shall not exceed, in the aggregate, 1,078,000 shares, except
as such number of shares shall be adjusted in accordance with the provisions of
ARTICLE X hereof. The maximum number of shares of Stock with respect to which
options may be granted to any single optionee during any calendar year shall not
exceed 60,000, except as such number of shares shall be adjusted in accordance
with the provisions of ARTICLE X.
The number of shares of Stock available for grant of options under the
Plan shall be decreased by the sum of the number of shares with respect to which
options have been issued and are then outstanding and the number of shares
issued upon exercise of options. In the event that any outstanding option under
the Plan for any reason expires, is terminated, or is cancelled prior to the end
of the period during which options may be granted, the shares of Stock called
for by the unexercised portion of such option may again be subject to an option
under the Plan.
ARTICLE IV
Eligibility of Participants
---------------------------
Subject to ARTICLE VII, officers and other key employees of the Company
or of its subsidiaries shall be eligible to receive options under the Plan. In
addition, options which are not incentive stock options may be granted to
directors, consultants, or other key persons who the Committee determines shall
receive options under the Plan.
2
<PAGE>
ARTICLE V
Option Price
------------
In the case of each incentive stock option granted under the Plan, the
option price shall be not less than the fair market value of the Stock at the
time the incentive stock option was granted. In the case of options other than
incentive stock options, the option price shall not be less than 50% of the fair
market value of the stock at the time the option was granted. The fair market
value shall be deemed for all purposes of the Plan to be the mean between the
highest and lowest sale prices reported as having occurred on any Exchange with
which the Company's Common Stock may be listed and traded on the date the option
is granted, or, if there is no such sale on that date, then on the last
preceding date on which such a sale was reported. If the Company's Common Stock
is not listed on any Exchange but the Common Stock is quoted in the National
Market System of the National Association of Securities Dealers Automated
Quotation System on a last sale basis then the fair market value of the Stock
shall be deemed to be the mean between the high and low price reported on the
date the option is granted, or, if there is no such sale on that date, then on
the last preceding date on which a sale was reported. If the Common Stock is not
quoted in the National Market System of the National Association of Securities
Dealers Automated Quotation System on a last sale basis, then the fair market
value of the Stock shall mean the amount determined by the Board to be the fair
market value based upon a good faith attempt to value the Stock accurately and
computed in accordance with applicable regulations of the Internal Revenue
Service. In no event shall the option price be less than the par value per share
of Stock on the date an option is granted.
ARTICLE VI
Exercise and Terms of Options
-----------------------------
The Committee shall determine the dates after which options may be
exercised, in whole or in part. If an option is exercisable in installments,
installments or portions thereof which are exercisable and not exercised shall
remain exercisable.
Any other provision of the Plan to the contrary notwithstanding and
subject to ARTICLE VII, no option shall be exercised after the date ten years
from the date of grant of such option (the "Termination Date").
Except as otherwise provided by the Committee at the time an option is
granted or by any amendment to an outstanding option:
3
<PAGE>
(i) If prior to the Termination Date, an optionee shall cease to be
employed by the Company or any subsidiary thereof by reason of a disability
within the meaning of Section 105(d)(4) of the Code, the option may remain
exercisable for a period not extending beyond one year after the date of
cessation of employment to the extent it was exercisable at the time of
cessation of employment.
(ii) In the event of the death of an optionee prior to the Termination
Date and while employed by the Company or a subsidiary thereof or while entitled
to exercise an option pursuant to the preceding paragraph, the optionee's
options may remain exercisable at any time prior to the Termination Date but in
no event later than one year from the date of death, by the person or person to
whom the optionee's rights under the option pass by will or the applicable laws
of descent and distribution to the extent that the optionee was entitled to
exercise it on the date of death.
(iii) If an optionee voluntarily terminates employment with the Company
for reasons other than death, disability, or retirement on or after the normal
retirement age set forth in the Company's policies (a "Voluntary Termination"),
or if an optionee's employment with the Company is terminated for Cause, as
hereinafter defined, unless otherwise provided by the Committee, all options
previously granted to such optionee which have not been exercised prior to such
termination shall lapse and be cancelled. If at the time of a Voluntary
Termination the Company was entitled to terminate the optionee's employment for
Cause, as hereinafter defined, all shares of Stock received pursuant to options
exercised after the Company was so entitled shall be purchased by the Company
for the exercise price of such shares paid by the optionee. If the Company
terminates an optionee's employment without Cause, as hereinafter defined,
unless otherwise provided by the Committee, all options previously granted to
such optionee which were exercisable immediately prior to such termination shall
continue to be exercisable for period not extending beyond three months after
the date of such termination.
For purposes of the Plan, the Company shall have "Cause" to terminate
an optionee's employment if the Company has cause to terminate the optionee's
employment under any existing employment agreement between the optionee and the
Company or, in the absence of an employment agreement between the optionee and
the Company, upon (A) the determination by the Board that the optionee has
ceased to perform his duties to the Company (other than as a result of his
incapacity due to physical or mental illness or injury), which failure amounts
to an intentional and extended neglect of his duties to the Company, (B) the
Board's determination that the optionee has engaged or is about to engage in
conduct materially injurious to the Company, or (C) the optionee having been
convicted of a felony.
4
<PAGE>
ARTICLE VII
Special Provisions Applicable to
Incentive Stock Options Only
----------------------------
The aggregate fair market value (determined as of the time the
option is granted) of the Stock with respect to which any incentive stock
options may be exercisable for the first time by the optionee in any calendar
year (under this Plan or any other stock option plan of the Company or any
parent or subsidiary thereof) shall not exceed $100,000. To the extent that such
aggregate fair market value exceeds $100,000 such options or portions thereof
shall be non-qualified stock options.
No incentive stock option may be granted to an individual who, at the
time the option is granted, owns directly, or indirectly within the meaning of
Section 424(d) of the Code, stock possessing more than 10 percent of the total
combined voting power of all classes of stock of the Company or of any parent or
subsidiary thereof, unless such option (i) has an option price of at least 110
percent of the fair market value of the Stock on the date of the grant of such
option; and (ii) such option cannot be exercised more than five years after the
date it is granted.
ARTICLE VIII
Payment for Shares
------------------
Payment for shares of Stock purchased under an option granted hereunder
shall be made in full upon exercise of the option, by certified or bank
cashier's check payable to the order of the Company, by the surrender or
delivery to the Company of shares of its Common Stock which have been held by
the optionee for at least six months, or by any other means acceptable to the
Company and designated by the Committee. The Stock purchased shall thereupon be
promptly delivered; provided, however, that the Company may, in its discretion,
require that an optionee pay to the Company, at the time of exercise, such
amount as the Company deems necessary to satisfy its obligation to withhold
Federal, state or local income or other taxes incurred by reason of the exercise
or the transfer of shares thereupon.
ARTICLE IX
Non-Transferability of Option Rights
------------------------------------
No option shall be transferable except by will or the laws of descent
and distribution. During the lifetime of the optionee, the option shall be
exercisable only by him.
5
<PAGE>
ARTICLE X
Adjustment for Recapitalization, Merger, Etc.
---------------------------------------------
The aggregate number of shares of Stock which may be issued pursuant to
options granted hereunder, the maximum number of shares which may be granted to
any single optionee during any calendar year, the number of shares of Stock
covered by each outstanding option and the price per share thereof in each such
option shall be appropriately adjusted for any increase or decrease in the
number of outstanding shares of stock resulting from a stock split or other
subdivision or consolidation of shares of Stock or for other capital adjustments
or payments of stock dividends or distributions or other increases or decreases
in the outstanding shares of Stock without receipt of consideration by the
Company.
In the event of any change in the outstanding shares of Stock by reason
of any recapitalization, merger, consolidation, spin-off, combination or
exchange of shares or other corporate change, or any distributions to common
shareholders other than cash dividends, the Committee shall make such
substitution or adjustment, if any, as it deems to be equitable, as to the
number or kind of shares of Stock or other securities issued or reserved for
issuance pursuant to the Plan, and the number or kind of shares of Stock or
other securities covered by outstanding options, and the option price thereof.
In instances where another corporation or other business entity is being
acquired by the Company, and the Company has assumed outstanding employee option
grants and/or the obligation to make future or potential grants under a prior
existing plan of the acquired entity, similar adjustments are permitted at the
discretion of the Committee. The Committee shall notify optionees of any
intended sale of all or substantially all of the Company's assets within a
reasonable time prior to such sale.
The foregoing adjustments and the manner of application of the
foregoing provisions shall be determined by the Committee in its sole
discretion. Any such adjustment may provide for the elimination of any
fractional share which might otherwise become subject to an option.
ARTICLE XI
No Obligation to Exercise Option
--------------------------------
Granting of an option shall impose no obligation on the recipient to
exercise such option.
6
<PAGE>
ARTICLE XII
Use of Proceeds
---------------
The proceeds received from the sale of Stock pursuant to the Plan shall
be used for general corporate purposes.
ARTICLE XIII
Rights as a Stockholder
-----------------------
An optionee or a transferee of an option shall have no rights as a
stockholder with respect to any share covered by his option until he shall have
become the holder of record of such share, and he shall not be entitled to any
dividends or distributions or other rights in respect of such share for which
the record date is prior to the date on which he shall have become the holder of
record thereof.
ARTICLE XIV
Employment Rights
-----------------
Nothing in the Plan or in any option granted hereunder shall confer on
any optionee any right to continue in the employ of the Company or any of its
subsidiaries, or to interfere in any way with the right of the Company or any of
its subsidiaries to terminate the optionee's employment at any time.
ARTICLE XV
Compliance with the Law
-----------------------
The Company is relieved from any liability for the non-issuance or
non-transfer or any delay in issuance or transfer of any shares of Stock subject
to options under the Plan which results from the inability of the Company to
obtain or in any delay in obtaining from any regulatory body having jurisdiction
all requisite authority to issue or transfer shares of Stock of the Company
either upon exercise of the options under the Plan or shares of Stock issued as
a result of such exercise if counsel for the Company deems such authority
necessary for lawful issuance or transfer of any such shares. Appropriate
legends may be placed on the stock certificates evidencing shares issued upon
exercise of options to reflect such transfer restrictions.
7
<PAGE>
ARTICLE XVI
Cancellation of Options
-----------------------
The Committee, in its discretion, may, with the consent of any
optionee, cancel any outstanding option hereunder.
ARTICLE XVII
Expiration Date of Plan
-----------------------
No option shall be granted hereunder after April 15, 2004.
ARTICLE XVIII
Amendment or Discontinuance of Plan
-----------------------------------
The Board may, without the consent of the Company's stockholders or
optionees under the Plan, at any time terminate the Plan entirely and at any
time or from time to time amend or modify the Plan, provided that no such action
shall adversely affect options theretofore granted hereunder without the
optionee's consent, and provided further that no such action by the Board,
without approval of the stockholders, may (a) increase the total number of
shares of Stock which may be purchased pursuant to options granted under the
Plan, except as contemplated in ARTICLE X or (b) decrease the minimum option
price.
8
